JP2013537182A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537182A5
JP2013537182A5 JP2013527670A JP2013527670A JP2013537182A5 JP 2013537182 A5 JP2013537182 A5 JP 2013537182A5 JP 2013527670 A JP2013527670 A JP 2013527670A JP 2013527670 A JP2013527670 A JP 2013527670A JP 2013537182 A5 JP2013537182 A5 JP 2013537182A5
Authority
JP
Japan
Prior art keywords
composition according
sodium
particles
polymer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013527670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/000785 external-priority patent/WO2012035283A1/en
Publication of JP2013537182A publication Critical patent/JP2013537182A/ja
Publication of JP2013537182A5 publication Critical patent/JP2013537182A5/ja
Ceased legal-status Critical Current

Links

JP2013527670A 2010-09-13 2011-05-23 医薬組成物 Ceased JP2013537182A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2522MU2010 2010-09-13
IN2522/MUM/2010 2010-09-13
IN2539/MUM/2010 2010-09-14
IN2539MU2010 2010-09-14
PCT/GB2011/000785 WO2012035283A1 (en) 2010-09-13 2011-05-23 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2013537182A JP2013537182A (ja) 2013-09-30
JP2013537182A5 true JP2013537182A5 (enExample) 2014-07-10

Family

ID=44169144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527670A Ceased JP2013537182A (ja) 2010-09-13 2011-05-23 医薬組成物

Country Status (13)

Country Link
US (1) US20130315988A1 (enExample)
EP (1) EP2616044A1 (enExample)
JP (1) JP2013537182A (enExample)
KR (1) KR20140029356A (enExample)
CN (1) CN103221032A (enExample)
AU (1) AU2011303715A1 (enExample)
BR (1) BR112013005772A2 (enExample)
CA (1) CA2810598A1 (enExample)
MX (1) MX2013002802A (enExample)
NZ (1) NZ607935A (enExample)
RU (1) RU2013113752A (enExample)
WO (1) WO2012035283A1 (enExample)
ZA (1) ZA201301920B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
IN2014MU00916A (enExample) * 2014-03-20 2015-09-25 Cipla Ltd
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
US20170202850A1 (en) 2014-07-21 2017-07-20 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
EP3525825B1 (en) * 2016-10-14 2024-03-20 Cipla Limited Pharmaceutical compositions comprising rifaximin
US20220184095A1 (en) * 2019-04-22 2022-06-16 Mylan Specialty L.P. Meloxicam co-crystal compositions
EP4171520A1 (en) * 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CN100490790C (zh) * 2007-04-28 2009-05-27 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
JP2009137922A (ja) * 2007-11-16 2009-06-25 Kaneka Corp リファマイシン誘導体を傷害組織にデリバリーする製剤
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체

Similar Documents

Publication Publication Date Title
JP2013537182A5 (enExample)
JP2013525337A5 (enExample)
RU2013113752A (ru) Фармацевтическая композиция
JP2010047579A5 (enExample)
AU2011244783B2 (en) Pharmaceutical compositions
JP2012136541A5 (enExample)
FI3033102T4 (fi) Peptidikonjugoituja hiukkasia
MY159172A (en) Inhalable particles comprising tiotropium
JP2013535505A5 (enExample)
JP2013542945A5 (enExample)
JP2013530158A5 (enExample)
JP2013519645A5 (enExample)
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
JP2011525477A5 (enExample)
JP2009280621A5 (enExample)
ZA202409847B (en) Gastro-resistant controlled release oral dosage forms
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2013011586A (es) Novedosos derivados polisacaridos y formas de administracion.
JP2012509281A5 (enExample)
CN104721156A (zh) 一种含利伐沙班的片剂
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
JP2012530146A5 (enExample)
MY164765A (en) Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
NZ607225A (en) Multiple unit tablet composition
MX2012013178A (es) Composicion antiparasitaria de amplio espectro de nitazoxanida, probioticos y prebioticos.